X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Kite will gain access to Epic Bio’s gene regulation platform to potentially develop next-generation cancer cell therapies and Epic Bio will develop constructs for Kite-selected targets for use in CAR T-cell therapies directed to blood cancers.
Lead Product(s): CAR T-cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Kite Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 31, 2023
Details:
The investment will support development of Epic’s lead program EPI-321, a novel therapeutic that is designed to correct the epigenetic alterations in the D4Z4 region of chromosome 4.
Lead Product(s): EPI-321
Therapeutic Area: Musculoskeletal Product Name: EPI-321
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Solve FSHD
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing April 18, 2023
Details:
EPI-321 is being studied for the treatment of Facioscapulohumeral Muscular Dystrophy (FSHD). FSHD is caused by a loss of methylation of the D4Z4 region, leading to an abnormal expression of the DUX4 gene on chromosome 4, normally only expressed during embryogenesis.
Lead Product(s): EPI-321
Therapeutic Area: Musculoskeletal Product Name: EPI-321
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2022
Details:
EP1-321, platform integrates its dCas proteins with customized guide RNA, in studiy of results from invitro it demonstrate the utility of our dCas to suppress DUX4 expression by up to 95%.
Lead Product(s): EPI-321
Therapeutic Area: Musculoskeletal Product Name: EPI-321
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
